Your browser doesn't support javascript.
A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.
Han, Xiaojian; Wang, Yingming; Li, Shenglong; Hu, Chao; Li, Tingting; Gu, Chenjian; Wang, Kai; Shen, Meiying; Wang, Jianwei; Hu, Jie; Wu, Ruixin; Mu, Song; Gong, Fang; Chen, Qian; Gao, Fengxia; Huang, Jingjing; Long, Yingyi; Luo, Feiyang; Song, Shuyi; Long, Shunhua; Hao, Yanan; Li, Luo; Wu, Yang; Xu, Wei; Cai, Xia; Gao, Qingzhu; Zhang, Guiji; He, Changlong; Deng, Kun; Du, Li; Nai, Yaru; Wang, Wang; Xie, Youhua; Qu, Di; Huang, Ailong; Tang, Ni; Jin, Aishun.
  • Han X; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Wang Y; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Li S; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Hu C; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Li T; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Gu C; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Wang K; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Shen M; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Wang J; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Hu J; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Wu R; Key Laboratory of Medical Molecular Virology, Department of Medical Microbiology and Parasitology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
  • Mu S; Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China.
  • Gong F; Department of Breast Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • Chen Q; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Gao F; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Huang J; Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Chongqing Medical University, Chongqing, China.
  • Long Y; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Luo F; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Song S; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Long S; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Hao Y; Department of Pediatrics, Yongchuan Hospital Affiliated to Chongqing Medical University, Chongqing, China.
  • Li L; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Wu Y; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Xu W; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Cai X; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Gao Q; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Zhang G; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • He C; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Deng K; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Du L; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Nai Y; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Wang W; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Xie Y; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Qu D; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Huang A; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Tang N; Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Jin A; Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
Front Immunol ; 12: 653189, 2021.
Article in English | MEDLINE | ID: covidwho-1172966
ABSTRACT
After the pandemic of COVID-19, neutralizing antibodies (NAbs) against SARS-CoV-2 have been developed for the prophylactic and therapeutic purposes. However, few methodologies are described in detail on how to rapidly and efficiently generate effective NAbs to SARS-CoV-2. Here, we integrated and optimized a strategically screening method for NAbs, which has enabled us to obtain SARS-CoV-2 receptor-binding domain (RBD) specific NAbs within 6 days, followed by additional 9 days for antibody production and function analysis. Using this method, we obtained 198 specific Abs against SARS-CoV-2 RBD from the blood samples of COVID-19 convalescent patients, and 96 of them showed neutralizing activity. At least 20% of these NAbs exhibited advanced neutralizing potency and high affinity, with the top two NAbs showing half-maximal inhibitory concentration (IC50) to block authentic SARS-CoV-2 at 9.88 and 11.13 ng/ml, respectively. Altogether, our study provides an effective methodology with high applicable value for discovering potential preventative and therapeutic NAbs for the emerging infectious diseases.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.653189

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 / Antibodies, Viral Limits: Humans Language: English Journal: Front Immunol Year: 2021 Document Type: Article Affiliation country: Fimmu.2021.653189